GlassScriptPhysician profile
Steven A Riczu
NPI 1780631283
$4,668.41
in general payments reported to CMS, 2019-2025
20 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $454 · 2022: $1,105 · 2023: $939 · 2024: $1,094 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,109.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.11 | 2022-2025 | |
| Abbott Laboratories | $716.00 | 2022-2024 | Freestyle Libre 3, Cardiomems, Mitraclip |
| Neurocrine Biosciences, INC. | $630.90 | 2022-2024 | Ingrezza |
| Corcept Therapeutics | $245.25 | 2024-2025 | Korlym |
| Amgen INC. | $239.36 | 2021-2022 | |
| Dexcom, INC. | $213.12 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Sanofi-Aventis U.S. LLC | $205.61 | 2024-2025 | |
| Novo Nordisk INC | $192.45 | 2021-2023 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $168.40 | 2022 | |
| Beta Bionics, INC. | $144.72 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $124.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.84 | 2022 | |
| Glaxosmithkline, LLC. | $123.64 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $121.13 | 2024 | Opsumit, Uptravi |
| Argenx US, INC. | $115.75 | 2025 | Vyvgart |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $114.75 | 2023 | Lybalvi |
| Xeris Pharmaceuticals, INC. | $113.85 | 2025 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $100.51 | 2025 | Twiist |
| Abiomed | $99.84 | 2025 | |
| Genzyme Corporation | $93.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Riczu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.